Ionis Pharmaceuticals Inc. diskutieren
Ionis Pharmaceuticals Inc.
WKN: A2ACMZ / Symbol: IONS / Name: Ionis Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
46,46 €
-0,06 %
Buy Ionis Pharmaceuticals Inc.
Buy Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is now covered by analysts at Raymond James. They set a "strong-buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $65.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $25.00 to $28.00. They now have a "sell" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $62.00 price target on the stock, up previously from $52.00.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Piper Sandler from $60.00 to $62.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Royal Bank of Canada from $65.00 to $70.00. They now have an "outperform" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Piper Sandler from $62.00 to $63.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $65.00 price target on the stock, up previously from $63.00.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $65.00 to $72.00. They now have an "outperform" rating on the stock.
Ratings data for IONS provided by MarketBeat
Neueste Beiträge
TD_Cowen in Regeneron Pharmaceuticals Inc. diskutieren